Clear Search

Showing 5 results for “Zinman B”.

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

J Am Heart Assoc 2022;11:e025045 DOI: 10.1161/JAHA.121.025045

Cardiovascular disease is highly prevalent, and represents a major burden in patients with both T2D and CKD. In the CREDENCE trial, canagliflozin reduced the risk of first composite cardiovascular events; this post hoc analysis evaluated the effect on total (first and recurrent) events. During the trial, a total of 883 cardiovascular events occurred in 634 patients; 72% were first and 28% were subsequent events. Analysis showed canagliflozin reduced first and total cardiovascular events by 26% and 29%, respectively, with consistent results across patient subgroups and by baseline cardiovascular history.

These findings provide further support for the benefit of continuing canagliflozin therapy after an initial event to prevent recurrent CV events.

Read more…

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

Circulation 2022;145:575–85 doi: 10.1161/CIRCULATIONAHA.121.055459

In this analysis by Shaman et al., semaglutide and liraglutide offered kidney-protective effects in patients with type 2 diabetes, especially those with pre-existing chronic kidney disease.

Read more…

Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relationship to Cardiorenal Outcomes

Diabetes Obes Metab 2022; doi:10.1111/dom.14670

In this study of adults with T2D and established CV disease, the proportion of patients at high steatosis risk decreased slightly in patients treated with empagliflozin compared with patients treated with placebo. Fibrosis risk was not reduced.

Read more…

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

N Engl J Med 2017;377:1228–39 DOI: 10.1056/NEJMoa1612917

The EXSCEL study showed that among patients with type 2 diabetes (T2D) with or without previous cardiovascular (CV) disease, the incidence of major adverse cardiovascular events (MACE) did not differ significantly between patients who received exenatide and those who received placebo.

Read more…

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

N Engl J Med 2016;375:311–22 DOI: 10.1056/NEJMoa1603827

The LEADER trial demonstrated CV benefits with liraglutide, and showed that the rate of the first occurrence of death from cardiovascular (CV) causes, nonfatal myocardial infarction (MI), or nonfatal stroke among patients with type 2 diabetes (T2D) was lower with liraglutide than with placebo.

Read more…